Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)

Hong Kong · Delayed Price · Currency is HKD

2.430

0.00 (0.00%)

Jun 18, 2026, 10:34 AM HKT

-39.25% (1Y)

Market Cap	591.50M -6.2%
Revenue (ttm)	50.00M
Net Income	-77.96M
EPS	-0.32
Shares Out	243.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,200
Open	2.200
Previous Close	2.430
Day's Range	2.200 - 2.430
52-Week Range	2.230 - 10.770
Beta	0.09
Analysts	n/a
Price Target	11.78 (+384.77%)
Earnings Date	Aug 11, 2026

About HKG:2185

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated ba... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 65

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2185

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements